Applications of 2',3'-Di-O-Acetyl-5'-Deoxy-5-Fuluro-D-Cytidine in Industrial Manufacturing

Our facility supplies 2',3'-Di-O-Acetyl-5'-Deoxy-5-Fuluro-D-Cytidine directly for global B2B partners in high-value chemical manufacturing. The following sections outline its concrete roles within advanced pharmaceutical and nucleoside intermediate sectors, based exclusively on its well-documented downstream uses. Each application highlights specific compliance requirements, formulation nuances, integration steps, and the resulting finished goods, ensuring clarity and traceability for business customers.

1. Nucleoside Analog Antiviral API Synthesis

Major pharmaceutical producers utilize this material as a crucial protected intermediate during multi-step synthesis of nucleoside analogues, especially in manufacturing fluorinated cytidine antiviral APIs. Downstream chemists leverage its acetylated and fluorinated functionalities to control selective deprotection and glycosylation steps, improving yields in scale-up production.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• U.S. FDA cGMP for APIs (21 CFR Part 210/211)
• Ph. Eur. (European Pharmacopoeia) monograph requirements for nucleoside analogs
• Chinese Pharmacopoeia quality specifications for pharmaceutical raw materials

Typical usage ratio

• Reaction molar ratio typically 1:1 relative to active nucleobase, with adjustments of ±10% based on batch yield and process route.
• Post-derivatization stage, material content is monitored and optimized to minimize unreacted substrate below 2%.

Downstream process integration

• Charged after fluorination stage as a key intermediate during glycosylation and subsequent de-protection steps under controlled anhydrous conditions.
• Undergoes selective hydrolysis and purification before final coupling with active pharmaceutical moieties.

Final product types

• Antiviral nucleoside active pharmaceutical ingredients (e.g., fludarabine-related compounds)
• Finished tablet and injectable drug formulations
• API intermediates for oncology use
• Export-grade bulk drugs compliant with EU and US regulatory markets

2. C-Glycoside Prodrug Intermediate Manufacturing

Specialty chemical manufacturers apply this compound as a fluorinated and acetyl-protected cytidine building block for further modification in the C-glycoside prodrug synthesis chain. Its acetyl groups allow stepwise transformation while preventing unwanted hydrolysis during downstream processing, supporting consistent batch reproducibility.

Industry compliance standards

• ISO 9001:2015 Quality Management System for chemical production
• EU REACH Registration, Evaluation, and Authorization compliance
• USP General Chapter <1040> on purity determination of chemical intermediates
• OECD GLP (Good Laboratory Practice) for non-clinical safety studies

Typical usage ratio

• Dosed at 0.8–1.2 equivalents per target prodrug precursor, depending on the yield required during C–C bond formation steps.
• Reaction mixture concentration maintained between 20-40 g/L to avoid solubility issues in large-scale reactor setups.

Downstream process integration

• Used after initial fluorination and acetylation, then incorporated into organometallic-catalyzed C-glycosylation reactions.
• Removal of acetyl groups performed post-coupling, followed by chromatographic purification and crystallization.

Final product types

• C-glycoside prodrug API intermediates
• Antiviral prodrug candidates for clinical trials
• High-purity research-grade nucleoside analogues

3. Reference Standard Bulk Supply for Analytical Laboratories

Accredited analytical service laboratories require certified batches of this cytidine derivative as primary and secondary chemical reference standards. It provides a fluorinated, acetyl-protected structural marker, supporting system suitability testing and method validation by QC teams in nucleoside analytics.

Industry compliance standards

• ISO/IEC 17025 Accreditation for chemical testing and calibration laboratories
• USP General Chapter <561> on reference standard materials
• International Conference on Harmonisation (ICH) Q2(R2) Validation of Analytical Procedures
• Chemical Reference Substance production under WHO TRS 1010 guidelines

Typical usage ratio

• Supplied as 99.5% purity standard; laboratories typically prepare working solutions at 10–100 μg/mL for HPLC or MS analysis.
• Standard injection volume calibrated per assay protocol, often 5–20 μL per run, depending on detector sensitivity.

Downstream process integration

• Weighed and dissolved immediately prior to method validation or calibration curve establishment in routine nucleoside analysis workflows.
• Used as positive control to benchmark lot-to-lot variations and test matrix effects in pharmaceutical or bulk chemical inspection.

Final product types

• Certified reference standards for internal laboratory use
• System suitability solutions for quality control laboratories
• Traceable calibration substances for regulatory submissions

4. Customizable R&D Scale Nucleoside Derivative Synthesis

Medicinal chemistry and contract research organizations select this material for small-batch exploratory projects targeting novel fluorinated nucleoside derivatives. It enables modular design of test compounds by allowing controlled substitution and deprotection at both the 2’,3’-acetyl and 5’-fluoro positions, offering precise structural diversification for SAR (structure–activity relationship) investigations.

Industry compliance standards

• OECD Guidelines for the Testing of Chemicals (for lab and pilot batches)
• Good Research Practice (GRP) for preclinical stage synthesis
• US NIH ARRA Compliance (if federally funded projects use the material)
• Internal company SOPs for hazardous material handling

Typical usage ratio

• Dosed in micromole to millimole scale, with working concentrations tailored per project: typically in the range of 1–5 mmol per reaction batch.
• Reagent excess limited to 1.05–1.2 equivalents for high-value exploratory synthesis, with usage logged to maintain project cost control.

Downstream process integration

• Material charged as the protected nucleoside starting block during initial condensation and coupling steps on laboratory reactors.
• Final de-acetylation and purification follows candidate structure confirmation before in vitro or cell-based screening occurs.

Final product types

• Novel nucleoside analogues for pharmaceutical R&D
• Small-scale candidate libraries for structure–activity screening
• Reference materials for academic or commercial synthesis studies

5. Bulk Supply for High-Purity Nucleoside API Precursors

Pharmaceutical manufacturers relying on vertical integration purchase this intermediate to support captive synthesis of regulated fluorinated nucleoside API precursors. Direct supply at >98% HPLC purity ensures minimal downstream impurity generation, critical for maintaining compliance in later GMP production stages.

Industry compliance standards

• WHO GMP for pharmaceutical excipients and intermediates
• Japan Pharmaceutical Raw Materials Standards (JPRMS)
• EMA Guidelines for starting/raw material acceptance
• Hazard Analysis and Critical Control Points (HACCP) for contamination risk reduction

Typical usage ratio

• Usage set at 0.95–1.10 molar equivalents per API synthesis batch, refined through routine process monitoring.
• Stock solution concentrations typically run from 30–60 g/L, adjusted upward when continuous-flow reactors are employed.

Downstream process integration

• Dispensed at the protected nucleoside intermediate stage, prior to final active pharmaceutical ingredient building steps.
• Processed through filtration and drying steps before entering validated synthetic campaigns.

Final product types

• Batched GMP-grade API precursors
• High-purity nucleoside intermediates for licensed drug production
• Exportable fluorinated cytidine materials